For patients with a rare genetic subtype of early stage non small cell lung cancer, the threat of recurrence after surgery has long cast a shadow over recovery. Now, a landmark study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests a targeted therapy may dramatically alter that prognosis. The drug selpercatinib, already approved for advanced cases, reduced the risk of cancer returning by 83% in patients with RET fusion positive tumors, offering a potential new standard of care for a group with historically limited options.
Clinical Significance
Non small cell lung cancer accounts for approximately 85% of all lung cancer diagnoses, with RET fusion mutations present in roughly 1 2% of cases. While rare, this genetic alteration has been associated with aggressive disease progression and poorer outcomes following standard treatment. The findings from this study, presented at the American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine, mark the first time a targeted therapy has demonstrated such a profound benefit in early stage disease for this subgroup.
Deep Dive and Research Findings
The phase 3 LIBRETTO 431 trial enrolled 212 patients with stage IB to IIIA RET fusion positive NSCLC who had undergone surgical resection. Participants were randomized to receive either selpercatinib, a highly selective RET inhibitor, or a placebo for up to three years. The primary endpoint was disease free survival, defined as the time from randomization to recurrence or death from any cause.
After a median follow up of 24 months, the results were striking. Patients treated with selpercatinib experienced an 83% reduction in the risk of recurrence or death compared to those receiving placebo. The median disease free survival had not yet been reached in the selpercatinib group, while it was 19.2 months in the placebo arm. The therapy was generally well tolerated, with the most common side effects including hypertension, elevated liver enzymes, and fatigue.
Dr. Justin Gainor, director of the Center for Thoracic Cancers at Massachusetts General Hospital and a co author of the study, noted that these findings could redefine post surgical care for RET fusion positive patients. "For years, we’ve had limited tools to prevent recurrence in early stage lung cancer, particularly for those with actionable genetic alterations," he said. "This study provides compelling evidence that targeted therapy can fill that gap."
Future Outlook and Medical Implications
The implications of this research extend beyond the immediate patient population. The success of selpercatinib in early stage disease raises questions about the potential role of targeted therapies in other genetic subtypes of NSCLC, such as those driven by EGFR or ALK mutations. It also underscores the growing importance of comprehensive genomic testing in early stage lung cancer, where identifying actionable mutations could guide adjuvant treatment decisions.
Regulatory agencies are likely to review these findings closely. Selpercatinib is already approved for advanced RET fusion positive NSCLC and thyroid cancer, but an expansion to include early stage disease could provide a new therapeutic avenue for thousands of patients worldwide. The study authors are also exploring whether longer durations of therapy or combinations with other agents might further improve outcomes.
Patient or Practitioner Guidance
For patients with early stage NSCLC, these findings highlight the critical importance of genetic testing. RET fusion mutations are not routinely screened for in all institutions, but this study makes a strong case for broader adoption. Patients who test positive for RET fusions may now have a powerful new option to discuss with their oncologists, particularly if they are at high risk of recurrence.
Clinicians should consider incorporating RET testing into standard post surgical workups for NSCLC, especially in cases where the tumor’s genetic profile was not assessed preoperatively. The side effect profile of selpercatinib, while manageable, requires careful monitoring, particularly for hypertension and liver function abnormalities. Patients should be counseled on the signs of these potential complications and the importance of adherence to therapy.
For those already diagnosed with RET fusion positive NSCLC, this study offers a reason for cautious optimism. While long term data are still needed, the early results suggest that selpercatinib could become a cornerstone of post surgical care, potentially transforming a once dire prognosis into a more hopeful outlook.
Key Takeaways
- Selpercatinib reduced the risk of lung cancer recurrence by 83% in patients with RET fusion positive early stage NSCLC, according to a phase 3 trial.
- The study is the first to demonstrate such a significant benefit of targeted therapy in early stage disease for this rare genetic subtype.
- These findings could lead to expanded approval of selpercatinib for post surgical use and reinforce the importance of genomic testing in early stage lung cancer.
- Patients with RET fusion positive NSCLC should discuss these results with their oncologists to explore potential treatment options.
Frequently Asked Questions
What is RET fusion positive non small cell lung cancer?
RET fusion positive NSCLC is a subtype of lung cancer characterized by a genetic alteration where the RET gene fuses with another gene, leading to uncontrolled cell growth. It accounts for about 1 2% of all NSCLC cases and is associated with more aggressive disease.
How does selpercatinib work?
Selpercatinib is a targeted therapy that inhibits the RET protein, which is overactive in cancers with RET fusions. By blocking this protein, the drug helps prevent cancer cells from growing and spreading.
Who is eligible for selpercatinib based on this study?
The study focused on patients with stage IB to IIIA RET fusion positive NSCLC who had undergone surgical resection. Eligibility for selpercatinib in clinical practice may depend on regulatory approvals and individual patient factors.
What are the side effects of selpercatinib?
Common side effects include hypertension, elevated liver enzymes, fatigue, dry mouth, and diarrhea. Patients should be monitored regularly for these and other potential complications.
Is selpercatinib approved for early stage lung cancer?
As of now, selpercatinib is approved for advanced RET fusion positive NSCLC and thyroid cancer. The recent study results may support future approvals for early stage disease, but patients should consult their oncologists for the latest guidance.
Medical Review: MedSense Editorial Board
DISCUSSION (0)
POST A COMMENT